The GLP-1 Forecast for 2024: Six Key Predictions
- White Paper
- GLP-1s
- 3 min read
Summary
According to leading indicators, consumer interest in GLP-1s shows no signs of abating in 2024. Strong demand will continue to spark innovation—as evidenced by the dozens of new formulations in the pipeline—yet cost and access will remain significant obstacles for employers and employees alike.
While GLP-1 medicines can be game changers in the management of obesity, we anticipate that they will also trigger a huge wave of cost increases for employers, payors, and our entire health system.
This white paper identifies six GLP-1 trends for the upcoming year and corresponding takeaways for employers looking to craft a proactive utilization and care management approach.
Key recommendations for employers include:
- Find programs anchored to behavior and lifestyle change to help employees maintain weight loss and reduce long-term medication dependency
- Offer workforces a full-spectrum approach from prevention to clinical treatment
- Identify partners who invest in long-term studies to test the efficacy of their care models
Download the free white paper to learn more.
Download the White Paper
By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.
Related Posts
- Blog
- Mental Health
- September 28
- 1 min read
Bring Noom to
your organization
Give your workforce a preview of what’s possible
for their physical and mental health.
